Discontinuation of Gene Therapy R&D for AT702, AT751 and AT753
A specific pipeline rationalization topic involving the discontinuation of research and development on the gene therapy programs AT702, AT751 and AT753, along with recognition of the associated impairment loss on intangible assets.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.